EUVIMEDEUVIMED entdecken
Crossref

68 Ga-Labeled Peptides Targeting Oxytocin Receptor in Breast Cancer Using Linchpin Chemistry for Tandem Peptide Cyclization and Radiometal Chelator Incorporation

Madinage Pawani Jayathri Perera, Susan Pike, Richard Yuen, Cody Bergman, Jenilee Woodfield, Melinda Wuest, Frank Wuest iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Madinage Pawani Jayathri Perera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2N4, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Oxytocin, Peptides, Cyclic, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Dianne and Irving Kipnes Foundation, New Frontiers in Research Fund - Transformation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains a leading cause of cancer-related death worldwide, partly due to disease heterogeneity and the lack of reliable biomarkers. The G protein-coupled oxytocin receptor (OTR) has emerged as a potential biomarker and therapeutic target in breast cancer, as its overexpression correlates with tumor growth and metastasis. OTR thus presents new opportunities for molecular imaging and targeted therapy in breast cancer. This study explores three novel 68Ga-labeled peptides as potential OTR-specific imaging agents. Their preclinical evaluation includes in vitro assays and positron emission tomography (PET) studies in breast cancer models. The work also introduces the application of linchpin chemistry with LP1 and LP2 as a novel strategy for attaching bifunctional chelating agents. This tandem approach not only enables efficient peptide cyclization but also facilitates radiometal incorporation, representing a versatile platform for the design of next-generation radiopharmaceuticals. Binding studies using an aequorin-based assay in CHO cells expressing human OTR revealed the following EC50 values: natGa-LP1-oxytocin (376 nM), natGa-DOTA-Lys8-oxytocin (1.38 nM), and natGa-LP2-oxytocin (123 nM). Radiolabeling with 68Ga was efficient and reproducible, consistently yielding high decay-corrected radiochemical yields of 52-74% and high radiochemical purity >98%. PET imaging demonstrated maximum MCF-7 tumor uptake for 68Ga-LP1-oxytocin (SUVmax 0.64 ± 0.10; n = 3) and 68Ga-LP2-oxytocin (SUVmax 0.64 ± 0.05; n = 7) at 10 min postinjection, whereas 68Ga-DOTA-Lys8-oxytocin reached comparable uptake (SUVmax 0.64 ± 0.12; n = 3) at 30 min. Notably, 68Ga-LP2-oxytocin showed superior background clearance and faster blood pool washout. Tumor uptake specificity was verified through competitive inhibition studies: predosing with oxytocin reduced tracer accumulation in a concentration-dependent manner at 10 min postinjection, with decreases of 33% at 50 μM and 68% at 300 μM, confirming selective OTR-mediated binding in vivo. Among the evaluated tracers, the novel 68Ga-LP2-oxytocin peptide demonstrated efficient radiolabeling, strong binding potency, and favorable in vivo characteristics, including uptake in estrogen receptor-positive MCF-7 tumors and superior background and clearance profiles. With further structural optimization, 68Ga-LP2-oxytocin holds promise as a PET radioligand for targeting OTR in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsReceptors, OxytocinPeptides, CyclicBiomarkers, TumorMolecular ImagingRadiopharmaceuticalsHumansFemaleChelating AgentsGallium RadioisotopesPositron-Emission TomographyCyclizationOxytocinCHO CellsCricetulusRadioactive TracersMCF-7 CellsAnimalsMiceRadioligand Assay

Substanzen

OXTR protein, humanReceptors, OxytocinPeptides, CyclicChelating AgentsGallium RadioisotopesGallium-68Biomarkers, TumorOxytocinRadioactive TracersRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2N4, Canada.
  • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta T6G 2X4, Canada.
  • Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.

ORCID-Profile: Frank Wuest

Förderung

  • Dianne and Irving Kipnes Foundation
  • New Frontiers in Research Fund - Transformation

Zitieren

APA

Perera, M. P. J., Pike, S., Yuen, R., Bergman, C., Woodfield, J., Wuest, M., & Wuest, F. (2025). 68 Ga-Labeled Peptides Targeting Oxytocin Receptor in Breast Cancer Using Linchpin Chemistry for Tandem Peptide Cyclization and Radiometal Chelator Incorporation. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00494

Vancouver

Perera MPJ, Pike S, Yuen R, Bergman C, Woodfield J, Wuest M, et al. 68 Ga-Labeled Peptides Targeting Oxytocin Receptor in Breast Cancer Using Linchpin Chemistry for Tandem Peptide Cyclization and Radiometal Chelator Incorporation. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00494

BibTeX
@article{Perera2025,
  author = {Perera, Madinage Pawani Jayathri and Pike, Susan and Yuen, Richard and Bergman, Cody and Woodfield, Jenilee and Wuest, Melinda and Wuest, Frank},
  title = {68 Ga-Labeled Peptides Targeting Oxytocin Receptor in Breast Cancer Using Linchpin Chemistry for Tandem Peptide Cyclization and Radiometal Chelator Incorporation},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00494}
}
Kostenlos starten →